Predictive Oncology (NASDAQ: POAI) CEO Raymond Vennare has issued a letter to shareholders, providing an overview of the company and a look at the significant progress the company has made in respect to validating its commercial platform and publishing its proof of concept. In the letter, Vennare noted that Predictive Oncology is now in a position where it can focus all of its energy and resources on conducting transactions with biopharmaceutical partners and drive adoption of its proprietary PEDAL(TM) platform. Vennare called PEDAL “the drug discovery engine that will ultimately drive the future growth of the company” and noted that it is the synergy and interoperability of PEDAL in concert with the company’s CLIA laboratory, biorepository of tumor samples and GMP facility that will transform our business. He also recognized the company’s team of world-class scientists and the significant and sustained investment in this company that has brought POAI to its present state. The shareholder letter summarized the company’s key achievements, including a concerted effort to rebrand and reposition Predictive Oncology as “a science-driven company utilizing proprietary artificial intelligence (‘AI’) to accelerate drug discovery and enable drug development.” The letter also provided a detailed description of the PEDAL platform, outlined market conditions, included a financial overview and explained upcoming plans. “The senior management and board of directors of Predictive Oncology have been entirely focused on addressing the most critical issues facing the company over the past few months: compliance with NASDAQ’s listing requirements, stabilizing the company’s equity, restoring investor confidence, negotiating agreements and executing new customer contracts,” stated Predictive Oncology CEO Raymond Vennare in the letter. “Our emphasis has been, and will continue to be, on closing deals, driving adoption of the PEDAL platform and satisfying existing contracts. Our proposals, negotiations and engagements range from fee-for-service, upfront compensation, short-term milestone payments and long-term royalty fees. Opportunities currently in the pipeline include national and international biopharmaceutical, biologics, therapeutics and cancer research organizations, as well as government agencies. We will continue to pursue every opportunity to reach and maintain NASDAQ compliance, expedite sales efforts, close on contracts and improve shareholder value.”
To view the full press release, visit https://ibn.fm/E9bXT
About Predictive Oncology Inc.
Predictive Oncology, a science-driven company on the leading edge of oncology drug discovery, offers an unrivaled suite of solutions for the biopharma industry. Through the integration of scientific rigor and machine learning, the company has developed the ability to advance molecules into medicine more confidently by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the world’s largest privately held biobank of more than 150,000 tumor samples. Predictive Oncology’s solutions additionally include tumor models, biologics development, formulation design, a GMP facility, a CLIA laboratory and substantial scientific domain expertise. For more information about the company, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
